Clinical Trial
Study Details
Study Overview
The purpose of this study is to:
* Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, and gait speed
* Demonstrate superiority of nucresiran compared to in-study vutrisiran with respect to serum transthyretin (TTR) levels
Contacts and Locations
Clinical Trial Site
Aurora, Colorado 80045
United States
Clinical Trial Site
Chicago, Illinois 60611
United States
Clinical Trial Site
Baltimore, Maryland 21287
United States
Clinical Trial Site
Boston, Massachusetts 02118
United States
Clinical Trial Site
Rochester, Minnesota 55905
United States
Clinical Trial Site
New York, New York 10016
United States
Clinical Trial Site
New York, New York 10032
United States
Clinical Trial Site
Chapel Hill, North Carolina 27514
United States
Clinical Trial Site
Nashville, Tennessee 37232
United States
Clinical Trial Site
Dallas, Texas 75246
United States
Clinical Trial Site
Houston, Texas 77030
United States
Clinical Trial Site
CP2000 Rosario
Argentina
Clinical Trial Site
Darlinghurst 2010
Australia
Clinical Trial Site
Woolloongabba 4102
Australia
Clinical Trial Site
Ribeirão Preto
14051-140
Brazil
Clinical Trial Site
Rio de Janeiro
22640-100
Brazil
Clinical Trial Site
São Paulo
04038-002
Brazil
Clinical Trial Site
Vancouver V5Z 1M9
Canada
Clinical Trial Site
2371 Égkomi
Cyprus
Clinical Trial Site
94000 Créteil
France
Clinical Trial Site
94270 Le Kremlin-Bicêtre
France
Clinical Trial Site
13005 Marseille
France
Clinical Trial Site
10117 Berlin
Germany
Clinical Trial Site
69120 Heidelberg
Germany
Clinical Trial Site
48149 Münster
Germany
Clinical Trial Site
115 28 Athens
Greece
Clinical Trial Site
715 00 Heraklion
Greece
Clinical Trial Site
Dublin
D24 NR0A
Ireland
Clinical Trial Site
50134 Florence
Italy
Clinical Trial Site
20133 Milan
Italy
Clinical Trial Site
35128 Padova
Italy
Clinical Trial Site
27100 Pavia
Italy
Clinical Trial Site
00168 Roma
Italy
Clinical Trial Site
Bunkyo C
113-8519
Japan
Clinical Trial Site
Kumamoto
860-8556
Japan
Clinical Trial Site
Matsumoto-shi
390-8621
Japan
Clinical Trial Site
Suita
565-0871
Japan
Clinical Trial Site
59100 Kuala Lumpur
Malaysia
Clinical Trial Site
1649-035 Lisbon
Portugal
Clinical Trial Site
4099-001 Porto
Portugal
Clinical Trial Site
Seoul
05030
South Korea
Clinical Trial Site
Seoul
06351
South Korea
Clinical Trial Site
08035 Barcelona
Spain
Clinical Trial Site
21005 Huelva
Spain
Clinical Trial Site
8907 L'Hospitalet de Llobregat
Spain
Clinical Trial Site
28040 Madrid
Spain
Clinical Trial Site
07198 Palma de Mallorca
Spain
Clinical Trial Site
113 61 Stockholm
Sweden
Clinical Trial Site
907 37 Umeå
Sweden
Clinical Trial Site
3010 Bern
Switzerland
Clinical Trial Site
Taipei, 10002
Taiwan
Clinical Trial Site
Taipei, 112
Taiwan
Clinical Trial Site
Taoyuan City, 33305
Taiwan
Clinical Trial Site
London
NW3 2QG
United Kingdom